Several models have been developed to predict nonsentinel lymph node (non-SN) status in patients with breast cancer with sentinel lymph node (SN) metastasis. The purpose of our investigation was to compare available models in a prospective, multicenter study.
INTRODUCTION
Sentinel lymph node (SN) biopsy can accurately stage the axilla in early breast cancer, and it causes less morbidity than axillary lymph node dissection (ALND). [1] [2] [3] It remains to be determined whether ALND is always required for women with positive SNs on final histology, given that 40% to 70% of these patients have no metastatic nonsentinel lymph nodes (non-SNs). [4] [5] [6] [7] [8] [9] The likelihood of non-SN metastasis depends on several factors, such as histologic primary tumor size, the size of SN metastasis, the number of positive SNs, the ratio of positive SNs to all removed SNs, and the extracapsular extension status of the positive SNs. 5, 6, [9] [10] [11] [12] [13] However, none of these characteristics by themselves can identify a subset of patients for whom ALND is unnecessary.
Several mathematical models have been developed to predict non-SN status in patients with breast cancer with SN metastasis. These include four nomograms (ie, the Memorial Sloan-Kettering Cancer Center [MSKCC] , and two recursive partitioning (RP) tools developed by Kohrt et al. 6 ,10-12,14-16 However, before being incorporated into routine clinical practice, such models must be validated in independent patient populations.
The aim of this article was to evaluate and compare the several tools in an independent, multicenter cohort of patients with breast cancer and positive SNs. Moreover, results were compared with an optimal logistic regression (OLR) model that was developed from the patient cohort. We also tested the accuracy of each model in the subgroup of patients with micrometastases or isolated tumor cells (ITC) in the SN.
PATIENTS AND METHODS

Study Population
From January 2004 to December 2007, data on 561 patients with breast cancer and positive SNs were prospectively recorded into a single database; patient data came from six institutions: Tenon Hospital (Paris, France; 47 patients), Paoli-Calmettes Cancer Center (Marseille, France; 223 patients), Paul Papin Cancer Center (Angers, France; 113 patients), Alexis Vautrin Cancer Center (Nancy, France; 51 patients), Jean Verdier hospital (Bondy, France; 15 patients), and Eugène Marquis Cancer Center (Rennes, France; 112 patients). No patients had neoadjuvant treatment before SN biopsy or ALND. All the patients signed an informed consent form. Table 1 describes the characteristics of the population, as well as tumor and histologic findings on 561 patients and on a subgroup of 246 patients with only SN micrometastases or ITC. None of the patients included in the current series had been previously included in a series used to develop a model. SN biopsy was performed as previously described.
10, 17 All patients included in this study had completion ALND. ALND was performed during the same procedure when the SN was positive by imprint cytology or frozen section, or when the primary tumor was more than 2 cm intraoperatively. A second operation was performed when either hematoxylin and eosin staining or immunohistochemistry revealed tumor cells in the SN postoperatively, including ITC. Pathologic SN examination methods were as reported previously.
10,17
Description of Several Mathematical Models
Nine models developed to predict non-SN metastasis in positive-SN patients using postoperative information were identified in the medical literature using PubMed. 6, [10] [11] [12] [14] [15] [16] 11, 12, 14, 15 Scoring systems are based on attribution of points for informative variables. Results are compared with a threshold that allows the separation of patients into low-risk or high-risk groups. The thresholds for the Tenon score (range, 0 to 7), MDA score (range, Ϫ2 to 4), and Saidi score (range, 0 to 5) were 3.5, 0, and 2, respectively. Two RP models were proposed by Kohrt et al: recursive partitioning with receiver operating characteristic (RP-ROC) and boosted Classification and Regression Trees (CART).
14 RP is nonparametric in nature; it imposes no a priori restrictions on the distributional forms of the predictor variables. The RP algorithm is simple and intuitive. At each step, the RP program determines threshold values for each variable that provide the best separation of patients into homogeneous groups. Subgroups were separated using either the RP-ROC method as described by Kraemer (software available from Sierra-Pacific Mental Illness Research, Education, and Clinical Centers ͓Palo Alto, CA͔), or the CART method. 18, 19 In the latter case, splits were chosen using the Gini criterion.
18
Data and Statistical Analysis
Clinical and pathologic data for each patient were recorded prospectively. The performance of each model was quantified with respect to discrimination, calibration, false negative (FN) rate, and clinical utility.
Discrimination. Discrimination (ie, whether the relative ranking of individual predictions is in the correct order) was quantified with the area under the receiver operating characteristic (ROC) curve (AUC). 20 The AUC is a summary measure of the ROC that reflects the ability of a test to discriminate between a diseased and a nondiseased subject across all possible levels of positivity. A 95% CI was calculated for each AUC. AUC ranges from 0 to 1, with 1 indicating perfect concordance, 0.5 indicating no better concordance than chance, and 0 indicating perfect discordance.
Calibration. Calibration (ie, agreement between observed outcome frequencies and predicted probabilities) was studied from graphical representations of the relationship between the observed outcome frequencies and the predicted probabilities (calibration curves). A calibration curve can be approximated by a regression line with intercept ␣ and slope ␤. These parameters can be estimated in an LRM with the event as outcome and the linear predictor as the only covariate. Well-calibrated models have ␣ ϭ 0 and ␤ ϭ 1. Therefore, a sensible measure of calibration is a likelihood ratio statistic testing the null hypothesis that ␣ ϭ 0 and ␤ ϭ 1. The statistic has a 2 distribution with 2 df (unreliability [U] statistic). 21 Individual predictions were either calculated from nomograms or were obtained from the original data for the scoring system. We also evaluated average (E average [E aver]) and maximal errors (E maximal [E max]) between predictions and observations obtained from a calibration curve. Calibration is not adequate to evaluate scores or tree-based models, which are intended to give a positive or negative result.
FN rate. For nomograms and RP tools, 10% or less cutoff values were considered to define the subgroup of patients with a low predicted probability of metastatic non-SN. For scores, positive and negative predictions were compared with observed issues.
Clinical utility. The main aim of tools is to identify the largest subgroup of patients with a low risk of non-SN involvement. For each model, we studied the number of patients predicted as negative by scores or having a probability of metastatic non-SN Յ 10% predicted by nomograms or RP models.
OLR model. Multiple linear regression analysis was applied to the population of 561 patients to evaluate the optimal performance on our population. Age, histologic primary tumor size, tumor type, histologic grade, lymphovascular space involvement, estrogen/progesterone receptor status, size of SN metastasis, histologic method of SN analysis, the total number of SNs removed, the numbers of positive and negative SNs, the ratio of positive SNs to all removed SNs, and extracapsular extension were input into the multiple linear regression model with a backward section of informative variables based on Akaike's information criterion. We used the bootstrapping technique to obtain relatively unbiased estimates (200 repetitions); this provides an estimate of the average optimism of the AUC when all data are included. The performance of the OLR (considering overoptimism or not) can be regarded as the maximum that can be expected for a model based on external data.
Evaluation of a subgroup of micrometastasis and ITC. We also tested the accuracy of each model in the subgroup of patients with only micrometastasis or ITC in the SN. Models usually provide poor results for this particular subgroup.
All analyses were performed using the R package with the Design, Hmisc, Rpart, and Verification libraries (http://lib.stat.cmu.edu/R/CRAN/).
RESULTS
Among the 561 patients, at least one non-SN was metastatic in 147 patients (26.2%). We studied the performance of the nine models in terms of discrimination (AUC), calibration, FN rate, and clinical utility (number of patients at low risk for non-SN). We first studied the whole population and then the subgroup of patients with only SN micrometastases or ITC in the SN.
Performance of the Models Over the Whole Population
Discrimination. ROC curves are plotted in Figure 1 . When applied to all 561 patients, the model with the highest AUC was the (Table  3 ). An OLR model to predict non-SN metastasis was developed from the data of this cohort. The AUC of the resulting model was 0.85 (95% CI, 0.83 to 0.88). The AUC, corrected by bootstrapping, was 0.84, suggesting that an AUC of more than 0.84 is not achievable in this cohort.
Calibration. Calibration plots are given in Figure 2 . Two of the four nomograms were well calibrated, with no significant difference between the predicted and the observed probability: Cambridge (P ϭ .1) and Mayo (P ϭ .08) nomograms. This means that the percentages predicted with other scoring methods were unsatisfactory when both low-and high-risk patients of this series were studied. The average difference (E aver) in predicted and calibrated probabilities ranged from 3% to 23%. The maximal difference (E max) ranged from 5% to 58%. With the OLR model, the P value of the U index was 1 and the average difference in predicted and calibrated probabilities was 1.6%. The P value obtained with the OLR model was as expected; the average difference provides an adequate estimation of the target error when using external models (Table 3) . (Table 3) .
Clinical utility. Because the aim of models is to identify the largest possible low-risk subgroup, we specifically studied this aspect. Two RP models and one score assigned more than one third of patients to the low-risk group: RP-ROC, 30.8%; CART, 33.2%; Tenon score, 48%. Except for the MSKCC nomogram (35.8%), other nomograms assigned most patients to the high-risk group (Table 3) .
Subgroup of Patients With Only SN Micrometastases or ITC
ROC curves are plotted in Figure 1 . The Tenon score outperformed other models with an AUC of 0.81 (95% CI, 0.76 to 0.87), an FN rate of 2.9% (six of 209), and 85% of patients assigned to the low-risk group. Two models had AUCs ranging from 0.7 to 0.8: the MSKCC and Stanford nomograms with AUCs of 0.72 (95% CI, 0.66 to 0.79) and 0.73 (95% CI, 0.68 to 0.79), respectively; these nomograms gave FN rates of 3.5% (five of 143) and 2.2% (two of 91), respectively. Only the MSKCC nomogram was well calibrated (P ϭ .1). The six other models gave AUCs lower than 0.7, with the Mayo nomogram showing a 10% higher FN rate. Five models assigned more than half the patients to the low-risk group for non-SN: MSKCC (58.1% of patients assigned), Tenon score (85%), MDA score (53.7%), RP-ROC (70.3%), and CART (75.6%). In contrast, the Mayo nomogram assigned only 4.1% of patients to this group (Table 3) .
DISCUSSION
This multicenter study evaluates and compares the performance of nine models currently available to predict non-SN status in patients with breast cancer with SN metastasis; the models were all applied to an independent population of patients with cancer.
6,10-12,14-16 Our study suggests that the different models do not perform equally well, especially for the subgroup of patients with only micrometastasis or ITC in the SN. We indicate evaluation methods that are available to assess model performance and guide clinical practice.
If many models have been developed, few validations have been reported, as shown in Table 4 . 11, 12, 14, 15, 17, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] We believe that our comparison of models and our use of a reasonable target (optimal regression model) will help clinicians to decide what scoring method to use.
Predictive factors of metastatic involvement of non-SLN can be separated into two categories: (1) breast tumors characteristics, and (2) metastatic sentinel lymph node characteristics. 34 Consequently, most of models used tumor size, and number, and burden of metastatic SN as variables. To these robust factors, some models add other variables: lymphovascular invasion could be interesting because for most authors, it indicates the lymphatic spreading of the tumor; however, its input in the model performance is not obvious according to our study: six models integrated this component without improving the results compared with other models. The ratio between positive and total number of nodes is probably more interesting because it combines the number of metastatic SNs and a surrogate for the exhaustiveness of axillary sampling. Some investigators have reported that a sampling of four nodes may provide adequate staging 35, 36 or may add information to SN biopsy. 37 We tested all models with respect to discrimination, calibration, FN rate, and patients assigned to the low-risk group. We found that different evaluations may point out different intrinsic abilities of models. For example, LRM outperformed scores in terms of calibration; this is an expected result because LRM provides continuous probabilities, whereas scores are designed to identify a low-risk group while neglecting individual predictions in the high-risk group.
Discrimination is a popular evaluation criterion. The AUC indicates whether the relative ranking of individual predictions is in the correct order. It does not reflect the accuracy of a model, and its clinical significance is poor. In contrast, the clinical significance of calibration is high: it reflects the accuracy of individual predictions. It is worth emphasizing that of the four nomograms, only Van Zee et al 12 provided calibration measurements. In our study, we calculated average (E aver) and maximal errors (E max) between predictions and observations obtained from calibration curve. This gives an idea of model performance when extrapolated to new patient populations. .08
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This is of particular importance for clinical practice because probabilities are announced to patients without a CI. To indicate a probability, ϮE max or E aver is more appropriate than providing only a probability, for example, "The risk of nonsentinel node metastases is theoretically 10% but it may vary between 4% and 16%." In fact, nomogram and scores can be used together to inform patients: a negative/positive result is very informative for clinical practice, whereas a quantified prediction is useful for risk assessment. Moreover, the decision for ALND is multivariate, based on patient age, comorbidities, implications for systemic treatment, and not on a model only. In our institutions, 3% of patients with metastatic SLN did not undergo ALND during the study period. This is unlikely that this low number could alter our results. In contrast, in a study published by Dauphine et al, 25 micrometastasis were under-represented because nine of the 14 patients with micrometastasis did not undergo ALND.
Apart from calibration and discrimination, two important criteria of model performance may help clinicians to decide what model to use: a model's FN rate and its ability to identify the largest subgroup of patients with a low risk of non-SN involvement. Nevertheless, the fact remains that no tools have been able to identify patients without any risk of non-SN metastasis. In this study, only two models-Tenon score and Stanford nomogramgave an FN rate less than 5% (4.4% and 4.9%, respectively), whereas a third of the tools had an FN rate higher than 10% (Mayo nomogram, Cambridge nomogram, and the Saidi score). An FN rate Ͻ 5% is often considered as a target value because this is the false-negative rate of ALND. 10, 12, 17, 25, 29 The low proportions of patients for whom ALND could be avoided clearly undermine the reliability of such scores and nomograms for routine clinical practice. For this criterion, the Tenon score outperformed other models, with 48% of patients identified at low risk for non-SN metastasis. Only three others models-MSKCC nomogram and the two RP models-assigned more than 30% of patients to the group for whom ALND could be avoided (Table 3) , whereas the other models assigned low proportions of patients to the low-risk group. Interestingly, these latter models also showed low clinical utility with their original patient cohorts, suggesting that our findings are not specific to the patient cohort in the present analysis.
The subgroup of patients with only micrometastases or ITC is investigated in studies like this one because most of these patients were negative for non-SN. 38 In theory, therefore, a model could perform better for this subset of patients than for the whole population. We found here that 44% of patients had only micrometastases or ITC in SN. This proportion was comparable to those reported by other studies. 6, 26, 29 Alran et al 22 tested the accuracy of the MSKCC nomogram in 588 patients and found that it was reliable for patients with macrometastatic SNs but not for those with micrometastatic SNs. 14, 22 To our knowledge, no other model has been evaluated for this specific subgroup.
In this study, we showed that the Tenon score is particularly accurate for this subgroup of patients, with an AUC of 0.81 (95% CI, 0.76 to 0.87) and an FN rate of 2.9% (six of 209). Only two other (Table 3) . In contrast to Alran et al, 22 we validated the MSKCC nomogram for this subgroup of patients. In their study, the MSKCC nomogram was used for positive SN biopsy findings regardless of the method of metastasis detection, and some patients had SN detection by blue dye only. This may explain why Alran et al 22 failed to validate the MSKCC nomogram in the subgroup of patients with micrometastatic SNs.
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